Expert Opinion on Investigational Drugs 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson's disease
Expert Opin Investig Drugs. 2023 Sep 27:1-6. doi: 10.1080/13543784.2023.2263357. Online ahead of print.ABSTRACTINTRODUCTION: Pathogenic mutations of the abundant leucine-rich repeat kinase 2 gene support the onset of familial and sporadic forms of Parkinson's disease. These genetic variants catalyze kinase activity by substrate phosphorylation. They promote the nigrostriatal neurodegenerative process, i.e. characterized by Lewy body formation.AREAS COVERED: This narrative review discusses leucine-rich repeat kinase 2 inhibitors as therapeutic concept for beneficial disease modification following a literature search.EXPERT ...
Source: Expert Opinion on Investigational Drugs - September 27, 2023 Category: Drugs & Pharmacology Authors: Thomas M üller Source Type: research
Insulin sensitizers in 2023: lessons learned and new avenues for investigation
Expert Opin Investig Drugs. 2023 Sep 27:1-9. doi: 10.1080/13543784.2023.2263369. Online ahead of print.ABSTRACTINTRODUCTION: 'Insulin sensitizers' derived discoveries of the Takeda Company in 1970s. Pioglitazone remains the best in class with beneficial pleiotropic pharmacology, although use is limited by tolerability issues. Various attempts to expand out of this class assumed the primary molecular target was the transcription factor, PPARγ. Findings over the last 10 years have identified new targets of thiazolidinediones (TZDs) that should alter the drug discovery paradigm.AREAS COVERED: We review structural classes of ...
Source: Expert Opinion on Investigational Drugs - September 27, 2023 Category: Drugs & Pharmacology Authors: Jerry R Colca Steven P Tanis Rolf F Kletzien Brian N Finck Source Type: research
Novel JAK inhibitors under investigation for systemic lupus erythematosus: - where are we now?
Expert Opin Investig Drugs. 2023 Sep 27. doi: 10.1080/13543784.2023.2264172. Online ahead of print.ABSTRACTINTRODUCTION: Glucocorticoids and immunosuppressants are used to treat systemic lupus erythematosus (SLE). However, patients with SLE have poor long-term prognoses. This can be attributed to organ damage caused by flare-ups and drug toxicity due to the administration of nonspecific treatment. Therefore, SLE should be treated using therapeutic agents specific to its pathology. Janus kinase (JAK) inhibitors exert multitargeted effects by blocking the signaling of multiple cytokines. The use of JAK inhibitors has been ap...
Source: Expert Opinion on Investigational Drugs - September 27, 2023 Category: Drugs & Pharmacology Authors: Shingo Nakayamada Yoshiya Tanaka Source Type: research
DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson's disease
Expert Opin Investig Drugs. 2023 Sep 27:1-6. doi: 10.1080/13543784.2023.2263357. Online ahead of print.ABSTRACTINTRODUCTION: Pathogenic mutations of the abundant leucine-rich repeat kinase 2 gene support the onset of familial and sporadic forms of Parkinson's disease. These genetic variants catalyze kinase activity by substrate phosphorylation. They promote the nigrostriatal neurodegenerative process, i.e. characterized by Lewy body formation.AREAS COVERED: This narrative review discusses leucine-rich repeat kinase 2 inhibitors as therapeutic concept for beneficial disease modification following a literature search.EXPERT ...
Source: Expert Opinion on Investigational Drugs - September 27, 2023 Category: Drugs & Pharmacology Authors: Thomas M üller Source Type: research
Insulin sensitizers in 2023: lessons learned and new avenues for investigation
Expert Opin Investig Drugs. 2023 Sep 27:1-9. doi: 10.1080/13543784.2023.2263369. Online ahead of print.ABSTRACTINTRODUCTION: 'Insulin sensitizers' derived discoveries of the Takeda Company in 1970s. Pioglitazone remains the best in class with beneficial pleiotropic pharmacology, although use is limited by tolerability issues. Various attempts to expand out of this class assumed the primary molecular target was the transcription factor, PPARγ. Findings over the last 10 years have identified new targets of thiazolidinediones (TZDs) that should alter the drug discovery paradigm.AREAS COVERED: We review structural classes of ...
Source: Expert Opinion on Investigational Drugs - September 27, 2023 Category: Drugs & Pharmacology Authors: Jerry R Colca Steven P Tanis Rolf F Kletzien Brian N Finck Source Type: research
Novel JAK inhibitors under investigation for systemic lupus erythematosus: - where are we now?
Expert Opin Investig Drugs. 2023 Sep 27. doi: 10.1080/13543784.2023.2264172. Online ahead of print.ABSTRACTINTRODUCTION: Glucocorticoids and immunosuppressants are used to treat systemic lupus erythematosus (SLE). However, patients with SLE have poor long-term prognoses. This can be attributed to organ damage caused by flare-ups and drug toxicity due to the administration of nonspecific treatment. Therefore, SLE should be treated using therapeutic agents specific to its pathology. Janus kinase (JAK) inhibitors exert multitargeted effects by blocking the signaling of multiple cytokines. The use of JAK inhibitors has been ap...
Source: Expert Opinion on Investigational Drugs - September 27, 2023 Category: Drugs & Pharmacology Authors: Shingo Nakayamada Yoshiya Tanaka Source Type: research
DNL151, DNL201 and BIIB094: experimental agents for the treatment of Parkinson's disease
Expert Opin Investig Drugs. 2023 Sep 27. doi: 10.1080/13543784.2023.2263357. Online ahead of print.ABSTRACTINTRODUCTION: Pathogenic mutations of the abundant leucine-rich repeat kinase 2 gene support onset of familial and sporadic forms of Parkinson's disease. These genetic variants catalyze kinase activity by substrate phosphorylation. They promote the nigrostriatal neurodegenerative process i.e. characterized by Lewy body formation.AREAS COVERED: This narrative review discusses leucine-rich repeat kinase 2 inhibitors as therapeutic concept for beneficial disease modification following a literature search.EXPERT OPINION: ...
Source: Expert Opinion on Investigational Drugs - September 27, 2023 Category: Drugs & Pharmacology Authors: Thomas M üller Source Type: research
Insulin sensitizers in 2023: lessons learned and new avenues for investigation
Expert Opin Investig Drugs. 2023 Sep 27:1-9. doi: 10.1080/13543784.2023.2263369. Online ahead of print.ABSTRACTINTRODUCTION: 'Insulin sensitizers' derived discoveries of the Takeda Company in 1970s. Pioglitazone remains the best in class with beneficial pleiotropic pharmacology, although use is limited by tolerability issues. Various attempts to expand out of this class assumed the primary molecular target was the transcription factor, PPARγ. Findings over the last 10 years have identified new targets of thiazolidinediones (TZDs) that should alter the drug discovery paradigm.AREAS COVERED: We review structural classes of ...
Source: Expert Opinion on Investigational Drugs - September 27, 2023 Category: Drugs & Pharmacology Authors: Jerry R Colca Steven P Tanis Rolf F Kletzien Brian N Finck Source Type: research
Investigational follicle-stimulating hormone receptor agonists for male infertility therapy
Expert Opin Investig Drugs. 2023 Sep 25. doi: 10.1080/13543784.2023.2263364. Online ahead of print.ABSTRACTINTRODUCTION: According to estimates by the World Health Organization, about 17.5% of the adult population - roughly 1 in 6 globally - experience infertility. The causes of male infertility remain poorly understood and have yet to be fully evaluated. Follicle-stimulating hormone (FSH) represents an available and useful therapeutic strategy for the treatment of idiopathic infertility.AREAS COVERED: We provide here an overview of the molecular mechanisms by which FSH stimulates Sertoli cells and the schemes, dosages, an...
Source: Expert Opinion on Investigational Drugs - September 25, 2023 Category: Drugs & Pharmacology Authors: Rossella Cannarella Cristina M B Petralia Rosita A Condorelli Antonio Aversa Aldo E Calogero Sandro La Vignera Source Type: research
< em > NF1 < /em > alterations in cancers: therapeutic implications in precision medicine
Expert Opin Investig Drugs. 2023 Sep 25. doi: 10.1080/13543784.2023.2263836. Online ahead of print.ABSTRACTINTRODUCTION: NF1 is a tumor suppressor gene encoding neurofibromin, an inhibitor of the RAS/MAPK and PI3K-AKT-mTOR signaling pathways. NF1 germline pathogenic variants cause the tumor predisposition syndrome neurofibromatosis type 1. Targeted therapies (MEK inhibitors) have been approved for benign nerve sheath tumors in neurofibromatosis type 1 patients. NF1 somatic alterations are present in ~ 5% of all human sporadic cancers. In melanomas, acute myeloid leukemias and lung adenocarcinomas, the NF1 somatic alteratio...
Source: Expert Opinion on Investigational Drugs - September 25, 2023 Category: Drugs & Pharmacology Authors: Jean-St éphane Giraud Ivan Bi èche Éric Pasmant Camille Tlemsani Source Type: research
Investigational follicle-stimulating hormone receptor agonists for male infertility therapy
Expert Opin Investig Drugs. 2023 Sep 25. doi: 10.1080/13543784.2023.2263364. Online ahead of print.ABSTRACTINTRODUCTION: According to estimates by the World Health Organization, about 17.5% of the adult population - roughly 1 in 6 globally - experience infertility. The causes of male infertility remain poorly understood and have yet to be fully evaluated. Follicle-stimulating hormone (FSH) represents an available and useful therapeutic strategy for the treatment of idiopathic infertility.AREAS COVERED: We provide here an overview of the molecular mechanisms by which FSH stimulates Sertoli cells and the schemes, dosages, an...
Source: Expert Opinion on Investigational Drugs - September 25, 2023 Category: Drugs & Pharmacology Authors: Rossella Cannarella Cristina M B Petralia Rosita A Condorelli Antonio Aversa Aldo E Calogero Sandro La Vignera Source Type: research
< em > NF1 < /em > alterations in cancers: therapeutic implications in precision medicine
Expert Opin Investig Drugs. 2023 Sep 25. doi: 10.1080/13543784.2023.2263836. Online ahead of print.ABSTRACTINTRODUCTION: NF1 is a tumor suppressor gene encoding neurofibromin, an inhibitor of the RAS/MAPK and PI3K-AKT-mTOR signaling pathways. NF1 germline pathogenic variants cause the tumor predisposition syndrome neurofibromatosis type 1. Targeted therapies (MEK inhibitors) have been approved for benign nerve sheath tumors in neurofibromatosis type 1 patients. NF1 somatic alterations are present in ~ 5% of all human sporadic cancers. In melanomas, acute myeloid leukemias and lung adenocarcinomas, the NF1 somatic alteratio...
Source: Expert Opinion on Investigational Drugs - September 25, 2023 Category: Drugs & Pharmacology Authors: Jean-St éphane Giraud Ivan Bi èche Éric Pasmant Camille Tlemsani Source Type: research
Pharmacological agents for bone fracture healing: talking points from recent clinical trials
This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the 2020 PRISMA statement. In April 2023, the following databases were accessed: PubMed, Web of Science, Google Scholar, Embase. All the randomized clinical trials investigating pharmacological agents for bone fracture healing were accessed. No time constraint was set for the search. The search was restricted to RCTs. No additional filters were used in the database search. Data from 19 RCTs (4067 patients) were collected. 78% (3160 of 4067) were women. The mean length of the follow-up was 9.3 months (range, 1-26 mo...
Source: Expert Opinion on Investigational Drugs - September 23, 2023 Category: Drugs & Pharmacology Authors: Filippo Migliorini Federico Cocconi Gianluca Vecchio Luise Sch äefer Julian Koettnitz Nicola Maffulli Source Type: research
Nanocrystalline gold (CNM-Au8): a novel bioenergetic treatment for ALS
Expert Opin Investig Drugs. 2023 Sep 23. doi: 10.1080/13543784.2023.2263368. Online ahead of print.NO ABSTRACTPMID:37740686 | DOI:10.1080/13543784.2023.2263368 (Source: Expert Opinion on Investigational Drugs)
Source: Expert Opinion on Investigational Drugs - September 23, 2023 Category: Drugs & Pharmacology Authors: Steve Vucic Matthew C Kiernan Source Type: research
SGLT2 inhibitors: an Evidence-Based Update on cardiovascular Implications
Expert Opin Investig Drugs. 2023 Sep 23. doi: 10.1080/13543784.2023.2263354. Online ahead of print.ABSTRACTINTRODUCTION: Sodium Glucose co-Transporter 2 (SGLT2) inhibitors (also known as 'gliflozins') represent a cornerstone to treat diabetes mellitus. Moreover, recent randomized clinical trials have demonstrated important cardioprotective effects of gliflozins, independent of the presence of diabetes. Herein, we summarize the recent therapeutic progress in the cardiovascular field obtained with SGLT2 inhibitors.AREA COVERED: This review critically examines the rationale and results of recent clinical studies examining the...
Source: Expert Opinion on Investigational Drugs - September 23, 2023 Category: Drugs & Pharmacology Authors: Imma Forzano Scott Wilson Angela Lombardi Stanislovas S Jankauskas Urna Kansakar Pasquale Mone Fahimeh Varzideh Varzideh Gaetano Santulli Source Type: research
